A
Arezou Khosroshahi
Researcher at Emory University
Publications - 61
Citations - 9563
Arezou Khosroshahi is an academic researcher from Emory University. The author has contributed to research in topics: IgG4-related disease & Medicine. The author has an hindex of 31, co-authored 53 publications receiving 7969 citations. Previous affiliations of Arezou Khosroshahi include Massachusetts Eye and Ear Infirmary & Harvard University.
Papers
More filters
Journal ArticleDOI
Consensus statement on the pathology of IgG4-related disease
Vikram Deshpande,Yoh Zen,John Kc Chan,Eunhee E Yi,Yasuharu Sato,Tadashi Yoshino,Günter Klöppel,J. Godfrey Heathcote,Arezou Khosroshahi,Judith A. Ferry,Rob C. Aalberse,Daniel Bloch,William R. Brugge,Adrian C Bateman,Mollie N. Carruthers,Suresh T. Chari,Wah Cheuk,Lynn D. Cornell,Carlos Fernandez-del Castillo,David G. Forcione,Daniel L. Hamilos,Terumi Kamisawa,Satomi Kasashima,Shigeyuki Kawa,Mitsuhiro Kawano,Gregory Y. Lauwers,Yasufumi Masaki,Yasuni Nakanuma,Kenji Notohara,Kazuichi Okazaki,Ji Kon Ryu,Takako Saeki,Dushyant V. Sahani,Thomas C. Smyrk,James Robert Stone,Masayuki Takahira,George Webster,Motohisa Yamamoto,Giuseppe Zamboni,Hisanori Umehara,John H. Stone +40 more
TL;DR: This statement proposes a terminology scheme for the diagnosis of IgG4-related disease that is based primarily on the morphological appearance on biopsy, and advocates the use of strict criteria for accepting newly proposed entities or sites as components of the IgG 4- related disease spectrum.
Journal ArticleDOI
International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease
Arezou Khosroshahi,Zachary S. Wallace,J. L. Crowe,Takashi Akamizu,Atsushi Azumi,M. N. Carruthers,Suresh T. Chari,Emanuel Della-Torre,Luca Frulloni,Hiroshi Goto,Phil A. Hart,Terumi Kamisawa,Shigeyuki Kawa,Mitsuhiro Kawano,Myung-Hwan Kim,Yuzo Kodama,Kensuke Kubota,Markus M. Lerch,Matthias Löhr,Yasufumi Masaki,Shoko Matsui,Tsuneyo Mimori,Seiji Nakamura,Takahiro Nakazawa,Hirotaka Ohara,Kazuichi Okazaki,Jay H. Ryu,Takako Saeki,Nicolas Schleinitz,Akira Shimatsu,Toru Shimosegawa,Hiroki Takahashi,Masayuki Takahira,Atsushi Tanaka,Mark Topazian,Hisanori Umehara,George J. Webster,Thomas E. Witzig,Motohisa Yamamoto,W. Zhang,Tsutomu Chiba,John H. Stone +41 more
TL;DR: A. H. Wallace, J. L. Carruthers, S. L€ ohr, Y. Khosroshahi, Z. Chari, E. Della-Torre, L. Frulloni, H.
Journal ArticleDOI
Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations
John H. Stone,Arezou Khosroshahi,Vikram Deshpande,John K.C. Chan,J. Godfrey Heathcote,Rob C. Aalberse,Atsushi Azumi,Daniel Bloch,William R. Brugge,Mollie N. Carruthers,Wah Cheuk,Lynn D. Cornell,Carlos Fernandez-del Castillo,Judith A. Ferry,David G. Forcione,Günter Klöppel,Daniel L. Hamilos,Terumi Kamisawa,Satomi Kasashima,Shigeyuki Kawa,Mitsuhiro Kawano,Yasufumi Masaki,Kenji Notohara,Kazuichi Okazaki,Ji Kon Ryu,Takako Saeki,Dushyant V. Sahani,Yasuharu Sato,Thomas C. Smyrk,James R. Stone,Masayuki Takahira,Hisanori Umehara,George Webster,Motohisa Yamamoto,Eunhee S. Yi,Tadashi Yoshino,Giuseppe Zamboni,Yoh Zen,Suresh T. Chari +38 more
TL;DR: John H. Stone, Arezou Khosroshahi, Vikram Deshpande, John K.Stone, Masayuki Takahira, Hisanori Umehara, George Webster, Motohisa Yamamoto, Eunhee Yi, Tadashi Yoshino, Giuseppe Zamboni, Yoh Zen, and Suresh Chari.
Journal ArticleDOI
Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease.
TL;DR: Treatment with rituximab led to prompt clinical and serologic improvement in these patients with refractory IgG4-RSD, and is a viable treatment option for this condition, suggesting that ritUXimab achieves its effects in IgG 4- RSD by depleting the pool of B lymphocytes that replenish short-lived IgG3-secreting plasma cells.
Journal ArticleDOI
Rituximab for IgG4-related disease: a prospective, open-label trial
Mollie N. Carruthers,Mark Topazian,Arezou Khosroshahi,Thomas E. Witzig,Zachary S. Wallace,Philip A. Hart,Vikram Deshpande,Thomas C. Smyrk,Suresh T. Chari,John H. Stone +9 more
TL;DR: Rituximab appears to be an effective treatment for IgG4-RD, even without concomitant GC therapy.